{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T13:38:04Z","timestamp":1761917884287,"version":"3.44.0"},"reference-count":9,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.kint.2019.03.032","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T05:07:27Z","timestamp":1563512847000},"page":"283-286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["SGLT2 inhibitors\u2019 interaction with other renoactive drugs in type 2 diabetes patients: still a lot to learn"],"prefix":"10.1016","volume":"96","author":[{"given":"Micha\u00ebl J.B.","family":"van Baar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosalie A.","family":"Scholtes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dani\u00ebl H.","family":"van Raalte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2019.03.032_bib1","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.03.032_bib2","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.03.032_bib3","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.kint.2019.02.033","article-title":"Analysis from the EMPA-REG OUTCOME\u00ae trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics","volume":"96","author":"Mayer","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.03.032_bib4","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2019.03.032_bib5","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1681\/ASN.V591684","article-title":"Renal\u00a0effects of oral prostaglandin supplementation after ibuprofen in diabetic subjects: a double-blind, placebo-controlled, multicenter trial","volume":"5","author":"Bakris","year":"1995","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.03.032_bib6","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1681\/ASN.V10112382","article-title":"The paradox of the low-renin state in diabetic nephropathy","volume":"10","author":"Price","year":"1999","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.03.032_bib7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/BF00265402","article-title":"Comparison of the renal effects of angiotensin converting enzyme inhibitor and calcium antagonist in hypertensive type 2 (non-insulin-dependent) diabetic patients with microalbuminuria: a randomised controlled trial","volume":"32","author":"Baba","year":"1989","journal-title":"Diabetologia"},{"key":"10.1016\/j.kint.2019.03.032_bib8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/BF02336678","article-title":"Renal effects of nicardipine, a calcium antagonist, in hypertensive type 2 (non-insulin-dependent) diabetic patients with and without nephropathy","volume":"38","author":"Baba","year":"1990","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.kint.2019.03.032_bib9","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.2337\/diab.35.11.1206","article-title":"Renal effects of\u00a0nicardipine, a calcium entry blocker, in\u00a0hypertensive type II diabetic patients with\u00a0nephropathy","volume":"35","author":"Baba","year":"1986","journal-title":"Diabetes"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253819304983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253819304983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:53:48Z","timestamp":1758761628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253819304983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0085253819304983"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2019.03.032","relation":{},"ISSN":["0085-2538"],"issn-type":[{"type":"print","value":"0085-2538"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT2 inhibitors\u2019 interaction with other renoactive drugs in type 2 diabetes patients: still a lot to learn","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2019.03.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2019.02.033","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}